Dr. Oliver Bolzern earned his Ph.D as a chemical engineer at the ETH Zurich. He started his professional career at Ciba-Geigy (later Novartis) in development and production both in Switzerland and the UK. Then he joined Siegfried AG, initially as plant manager in Switzerland and later as Director of Operations for the two sites in the USA. In 2002 he moved to the predecessor company Noveon GmbH & Co. KG in Germany as Managing Director. In 2006 he founded PharmaZell via a management buyout with a private equity investor. Currently he is the CEO of the PharmaZell group with their five production sites in Europe and India.
Dr. Dirk Kirschneck is the founder and CEO of Microinnova Engineering GmbH. Based on his many years of research and development activities, he already gained international reputation and is considered as one of the leading experts in the field of chemical process intensification. He has held the position of the Key Researcher in two EU research projects in the 7th Framework Program. He is the Industry Representative of the Austrian Chemical Society of the working group process intensification of the European Federation of Chemical Engineering EFCE. Dr. Dirk Kirschneck has been studying at the University of Hamburg and worked as a research associate at the Institute for Thermal Processes and Environmental Engineering at the Technical University of Graz. He regularly gives lectures and seminars at international academic and business conferences. He also published several books as a professional author and writes for specialist magazines.
Mag. Ortwin Ertl founded IEP GmbH, Wiesbaden in 1999 and was its CEO until the end of 2006. In this period IEP developed into a profitable technology company with a focus on bio-reduction processes for the production of chiral hydroxy compounds. From 1995 to 1999 Mr. Ertl was consultant for several biotechnology companies, he headed Phyton GmbH, which was engaged in scale-up activities for the manufacture of Paclitaxel (a leading cytostatic drug), and prepared the foundation of IEP. From 1993 to 1995 he worked in marketing of pharmaceutical active ingredients and in technology marketing with Helm AG, Hamburg. After finishing his studies with an MBA in business administration at the Vienna University of Economics he studied business Japanese in Tokyo in 1991/92.
Prof. Dr. Ernst-Günter Afting was from 1995 until his retirement in 2006 President of the National Research Center for Environment and Health (GSF) in Munich, one of the biggest national research centers in Germany. Between 1993 and 1995 he was President and CEO of Roussel Uclaf in Paris, a subsidiary of Hoechst AG. Professor Afting had previously held various positions within the Hoechst AG since 1984. Among others, he was Member of the Board of Behring-Werke, Marburg from 1984 to 1989; Head of world-wide Pharma Research of Hoechst AG from 1989 to 1991; Chairman of the Pharmaceutical Division of Hoechst (with 35,000 employees worldwide) from 1991 to 1993. Professor Afting holds degrees in Medicine and Chemistry (M.D., Ph.D.) and is a member emeritus of the medical faculty at the University of Goettingen.
Prof. Afting was a member of the Advisory Committee on Science and Technology to the German Chancellor Kohl from 1996 to 1997 and has been a Member of the National Advisory Committee on Health to the Ministers of Science/Technology and Health from 1996 to 2005. During the recent years Prof. Afting was scientific advisor to several companies e.g. Siemens Medical Solutions, Erlangen, Olympus Europe, Hamburg and Biotest, Frankfurt.
At present Prof. Afting is a member of the advisory committee “Biotechnology” to the Minister of Economics of the State of Bavaria, serves on several supervisory boards of entrepreneurial biotechnology companies: e.g. Enanta Pharmaceuticals, Boston, Sequenom Inc. and Sorrento Therapeutics, both in San Diego and is Chairman of the Supervisory Board of the Biotech Cluster BioM in Munich.